Is ketamine a litmus test for capacity in assisted dying with depression?

Rosenblat, Joshua D.; Li, Madeline

doi:10.1002/pon.5586

Cited by 4 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…He remained firm in his decision to receive MAiD. 54 The patient reported transient drowsiness and confusion.…”

Section: Resultsmentioning

confidence: 99%

“…Rosenblat & Li 54 reported on three hospice patients aged 60-80 years who requested medical assistance in dying (MAiD) and received intranasal ketamine doses (50-150 mg) at 3-day intervals. One patient with cancer, who had a poor prognosis, responded to ketamine and had improved motivation, drive, and energy.…”

Section: Resultsmentioning

confidence: 99%

“…Overall, all case series reported positive therapeutic effects. Iglewicz et al 52 reported an early response (1-3 days), which was sustained for 7 days; Latuga et al 53 reported a robust and sustained improvement that lasted 1-7 weeks; Rosenblat & Li 54 reported subjective mood improvement for all patients within the treatment timeframe (9 days).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of ketamine for the treatment of depressive symptoms in palliative care: A systematic review

Barbosa¹,

Garcia²,

Sarin³

et al. 2023

Brazilian Journal of Psychiatry

View full text Add to dashboard Cite

Objectives: Ketamine has a fast onset of action that may offer a paradigm change for depression management at the end of life. We aimed to synthesize evidence regarding the safety and efficacy of ketamine in depression treatment within a broad palliative care concept. Methods: We searched seven databases and included studies on the safety and efficacy of ketamine for depression treatment in patients diagnosed with any life-threatening disease. We also conducted a narrative review of the evidence. Results: Among 2,252 screened titles and abstracts, we included 32 studies in our final synthesis: 14 case reports, two case series, two quasi-experimental studies, and seven randomized clinical trials (RCTs), as well as data from three unpublished clinical trials and seven cases from four larger case series. Most case reports reported a robust effect; however, the larger studies reported conflicting findings. Five RCTs reported positive outcomes; however, four of them were focused on a perioperative setting. Two negative studies did not primarily focus on depression and did not apply severity cutoffs. Conclusion: Although ketamine is generally safe and potentially useful, its efficacy in palliative care settings remains unclear. It may be a reasonable alternative for perioperative depression in oncological patients.

show abstract

“…He remained firm in his decision to receive MAiD. 54 The patient reported transient drowsiness and confusion.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%